Physician profile
Anna Rountree
NPI 1427598333
$3,501.08
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $590 · 2022: $1,699 · 2023: $897 · 2024: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $368.79 | 2021-2024 | |
| Janssen Biotech, INC. | $216.41 | 2021-2024 | Rybrevant |
| Apellis Pharmaceuticals, INC. | $177.11 | 2022-2023 | Empaveli |
| Abiomed | $173.68 | 2024 | Impella |
| Acrotech Biopharma INC. | $169.81 | 2022-2023 | Beleodaq |
| Merck Sharp & Dohme LLC | $150.62 | 2021-2023 | Keytruda, Lynparza |
| Amgen INC. | $141.08 | 2021-2023 | Lumakras |
| Takeda Pharmaceuticals U.S.A., INC. | $137.05 | 2021-2023 | Ninlaro |
| Beigene USA, INC. | $132.17 | 2021-2023 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $125.19 | 2021-2023 | |
| Lilly USA, LLC | $117.91 | 2022-2023 | Verzenio, Jaypirca, Retevmo |
| Pfizer INC. | $114.47 | 2021-2023 | |
| Genzyme Corporation | $113.06 | 2022-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $106.81 | 2021-2023 | Imbruvica |
| Gilead Sciences, INC. | $86.91 | 2021-2024 | Trodelvy |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Rountree listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.